Get it on Google Play

Beam Therapeutics reports early trial data for GSDIa gene therapy

October 13, 2026 7:00 AM EDT Send to a Friend
Beam Therapeutics Inc. (Nasdaq: BEAM) announced it will present initial data from its ongoing Phase 1/2 clinical trial of BEAM-301 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login